Intracellular redox state as determinant for melatonin antiproliferative vs cytotoxic effects in cancer cells

Free Radical Research

Volumn 45, Issue 11-12, 2011, Pages 1333-1341

  Sánchez Sánchez, Ana M ^a,b   Martín, Vanesa ^a,b   García Santos, Guillermo ^a,b   Rodríguez Blanco, Jezabel ^a   Casado Zapico, Sara ^a,b   Suarez Garnacho, Santos ^a   Antolín, Isaac ^a,b   Rodriguez, Carmen ^a,b  

^a UNIVERSIDAD DE OVIEDO   (Spain)

^b DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

Author keywords

Cancer; Cell death; Melatonin; Proliferation; Redox state

Indexed keywords

MELATONIN; REACTIVE OXYGEN METABOLITE;

ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CELL; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; OXIDATION REDUCTION STATE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; GLUTATHIONE; HUMANS; MELATONIN; NEOPLASMS; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES;

EID: 80555127478     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2011.623700     Document Type: Article

References (39)

1. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991;12:151-80.
2. Vanecek J. Cellular mechanisms of melatonin action. Physiol Rev 1998;78:687-721. (Pubitemid 28340600)
3. Tan DX, Chen LD, Poeggeler B, Manchester LC and Reiter RJ. Melatonin: a potent endogenous hydroxyl radical scavenger. Endocrine Journal 1993;1:57-60.
4. Galano A, Tan DX, and Reiter RJ. Melatonin as a naturalally against oxidative stress: a physicochemical examination. J Pineal Res 2011;51(1):1-16.
5. Tamarkin L, Cohen M, Rosell D, Reichert C, Lippman M and Chabner B. Melatonin inhibition and pinealectomy enhacement of dimethylbenz(a)anthracene- induced mammary tumors in the rat. Cancer Res 1981;41:4432-4436. (Pubitemid 12201353)
6. Pierpaoli W and Regelson W. Pineal control of aging: effect of melatonin and pineal grafting on aging mice. Proc Natl Acad Sci USA 1994;91:787-791. (Pubitemid 24041487)
7. Vijayalaxmi, Thomas CR, Reiter RJ and Herman TS. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 2002;20:2575-2601. (Pubitemid 34525746)
8. Blask DE, Sauer LA and Dauchy RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadianbased cancer therapy. Curr Top Med Chem 2002;2:113-132.
9. Cos S, Fernandez R, Guezmes A and Sanchez-Barcelo EJ. Infl uence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res 1998; 58:4383-4390. (Pubitemid 28450041)
10. Moretti MM, Limonta P, Maggi R, Motta M and Moretti RM. Growth-inhibitory activity of melatonin on human androgen-independent DU 145 prostate cancer cells. Prostate 2000;45:238-244.
11. Sainz RM, Mayo JC, Tan DX, Lopez-Burillo S, Natarajan M and Reiter RJ. Antioxidant activity of melatonin in Chinese hamster ovarian cells: changes in cellular proliferation and differentiation. Biochem Biophys Res Commun 2005;302:625-634. (Pubitemid 36279577)
12. Martin V, Herrera F, Carrera-Gonzalez P, Garcia-Santos G, Antolin I, Rodriguez-Blanco J and Rodriguez C. Intracellular signaling pathways involved in the cell growth inhibition of glioma cells by melatonin. Cancer Res 2006;66:1081-1088. (Pubitemid 43165976)
13. Casado-Zapico S, Rodriguez-Blanco J, Garcí a-Santos G, Mart í n V, S á nchez-S á nchez AM, Antol í n I and Rodriguez C. Synergistic antitumor effect of melatonin with several chemotherapeutic drugs on human Ewing sarcoma cancer cells: potentiation of the extrinsic apoptotic pathway. J Pineal Res 2010;48:72-80.
14. Mart í n V, Garc í a-Santos G, Rodriguez-Blanco J, Casado-Zapico S, Sanchez-Sanchez A, Antol í n I, et al. Melatonin sensitizes human malignant glioma cells against TRAIL-induced cell death. Cancer Lett 2010;287:216-223.
15. Garc í a-Santos G, Antolí n I, Herrera F, Martí n V, Rodriguez-Blanco J, del Pilar Carrera M and Rodriguez C. Melatonin induces apoptosis in human neuroblastoma cancer cells. J Pineal Res 2006;41:130-135. (Pubitemid 44141747)
16. Leja-Szpak A, Jaworek J, Pierzchalski P and Reiter RJ. Melatonin induces pro-apoptotic signaling pathway in human pancreatic carcinoma cells (PANC-1). J Pineal Res 2010;49(3):248-255.
17. Bü yü kavci M, Ozdemir O, Buck S, Stout M, Ravindranath Y and Sava ş an S. Melatonin cytotoxicity in human leukemia cells: relation with its pro-oxidant effect. Fundam Clin Pharmacol 2006;20(1):73-79.
18. Casado-Zapico S, Martí n V, Garc í a-Santos G, Rodrí guez-Blanco J, S á nchez-S á nchez AM, Lu ñ o E, et al. Regulation of the expression of death receptors and their ligands by melatonin in haematological cancer cell lines and in leukaemia cells from patients. J Pineal Res 2011;50(3):345-3655.
19. Molis TM, Spriggs LL, and Hill SM. Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol Endocrinol 1994;8:1681-1690.
20. Del R í o B, Garcí a Pedrero JM, Martinez-Campa C, Zuazua P, Lazo PS, and Ramos S. Melatonin, an endogenous-specifi c inhibitor of estrogen receptor alpha via calmodulin. J Biol Chem 2004;279:38294-38302. (Pubitemid 39295977)
21. Rimler A, Culig Z, Levy-Rimler G, Lupowitz Z, Klocker H, Matzkin H, et al. Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity. Prostate 2001;49:145-54. (Pubitemid 32937811)
22. Winczyk K, Pawlikowski M, Guerrero JM and Karasek M. Possible involvement of the nuclear RZR/ROR-alpha receptor in the antitumor action of melatonin on murine Colon 38 cancer. Tumour Biol 2002;23:298-302. (Pubitemid 36302487)
23. Blask DE, Sauer LA, Dauchy RT, Holowachuk EW, Ruhoff MS and Kopff HS. (1999). Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events. Cancer Res 59:4693-4701. (Pubitemid 29428978)
24. Sainz RM, Mayo JC, Tan DX, Leon J, Manchester L and Reiter RJ. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate 2003;63:29-43. (Pubitemid 40365388)
25. Denizot F and Lang R. Rapid colorimetric assay for cell growth and survival. J. Inmunol Methods 1986;89:271-277.
26. Bass DA, Parce JW, Dechatelet LR, Szjda P, Seeds MC and Thomas M. Flow citometric studies of oxidative product formation by neutrophils: a grade response to membrane stimulation. J Inmunol 1983;130:1910-1917. (Pubitemid 13091657)
27. Bonnefont-Rousselot D and Collin F. Melatonin: action as antioxidant and potential applications in human disease and aging. Toxicology 2010;278(1):55-67.
28. W öl fl er A, Caluba HC, Abuja PM, Dohr G, Schauenstein K and Liebmann PM. Prooxidant activity of melatonin promotes fas-induced cell death in human leukemic Jurkat cells. FEBS Lett 2001;502(3):127-131. (Pubitemid 32728274)
29. Pelicano H, Carney D and Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Update 2004;7(2):97-110. (Pubitemid 38736063)
30. Finkel T. Reactive oxygen species and signal transduction. IUBMB Life 2001;52:3-6. (Pubitemid 33769662)
31. Toyokuni S, Okamoto K, Yodoi J and Hiai H. Persistent oxidative stress in cancer. Febs Lett 1995;358(1):1-3.
32. Szatrowski TP, and Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991;51:794-798.
33. Chinery R, Beauchamp RD, Shyr Y, Kirkland SC, Coffey RJ and Morrow JD. Antioxidants reduce cyclooxigenase-2 expression, prostaglandin production, and proliferation in colorectal cancer cell. Cancer Res 1998;58(11):2323-2327. (Pubitemid 28252686)
34. DeFlora S, Balansky RM, Bennicelli C, Camoirano A, D; Agostini F, Izzotti A and Cesarone CF. Mechanism of anticarcinogenesis: the example of N-acetylcysteine. In: Ioannides C, Lewis DFV (eds). Drugs, diet and disease, vol 1. Mechanism Approaches to Cancer. Ellis Horwood, Hemel Hempstead, UK, 1995. pp. 151-203.
35. Tan DX, Reiter RJ, Manchester LC, Yan MT, El-Sawi M, Sainz RM, et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2002;2(2): 181-97.
36. Reiter RJ and Tan DX. What constitutes a physiological concentration of melatonin? J Pineal Res 2003;34(1):79-80. (Pubitemid 36140362)
37. Rodriguez C, Mayo JC, Sainz RM, Antol í n I, Herrera F, Mart í n V and Reiter RJ. Regulation of antioxidant enzymes: a signifi cant role for melatonin. J Pineal Res 2004;36(1):1-9. (Pubitemid 38130283)
38. Sainz RM, Reiter RJ, Tan DX, Roldan F, Natarajan M, Quiros I, et al. Critical role of glutathione in melatonin enhancement of tumor necrosis factor and ionizing radiationinduced apoptosis in prostate cancer cells in vitro. J Pineal Res 2008;45(3):258-270.
39. Daya RM and Suzukib YJ. Cell Proliferation, Reactive Oxygen and Cellular Glutathione. Dose Response 2005;3(3):425-442.